Showing results (311-320 of 344) with videos related to

Sort By:
Pageof 35
Journal of Hepatology|April 11, 2022
Rare ATG7 genetic variants predispose patients to severe fatty liver diseaseGuido A Baselli, Oveis Jamialahmadi, Serena Pelusi, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2011
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian WorkshopGiampiero Carosi, Mario Rizzetto, Alfredo Alberti, et al.
Hepatitis Monthly|November 2, 2016
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineSeyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, et al.
Gut|August 22, 2014
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationLindsay Y King, Claudia Canasto-Chibuque, Kara B Johnson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus BevacizumabLeonardo Stella, Giuseppe Cabibbo, Ciro Celsa, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practiceJeffrey V Lazarus, Laurent Castera, Henry E Mark, et al.
Pageof 35